Aisling Capital, a NYC-based investment firm that invests in companies developing and commercializing innovative healthcare products, services and technologies, added Eric Aguiar, MD, as a Partner.
Dr. Aguiar brings to Aisling experience in drug development, commercialization and strategic leadership. He will invest in biopharma opportunities across a range of therapeutic areas and stages of development.
Prior to joining Aisling, Dr. Aguiar was a Partner at Thomas, McNerney & Partners and before that he was a Managing Director of HealthCare Ventures, both healthcare focused venture capital firms.
He currently sits on the board of Invitae Corporation (formerly Locus Development, Inc.). His prior board seats have included Amarin, Oriel Therapeutics, Inc. (acquired by Novartis AG), Virdante Pharmaceuticals, Inc. (acquired by Momenta Pharmaceuticals), CardioKine, Inc. (acquired by Cornerstone Therapeutics), SkinMedica, Inc. (acquired by Allergan), Vaxinate, Inc., Metaphore, and 3-D Pharmaceuticals (acquired by Johnson & Johnson).
Aguiar was CEO of Genovo, Inc. (acquired by Targeted Genetics), a biopharmaceuticals company that specialized in gene delivery and gene regulation, executive director of TheraTech, Inc. (acquired by Watson Pharmaceuticals), Vice President and Managing Director of Philadelphia Ventures from 1992 to 1997.
Led by Steve Elms and Drew Schiff, Managing Partners, Aisling Capital invests in companies advancing pharmaceuticals, biotech, and medical products, and providing drug development, manufacturing and other services to the healthcare industry. Have a look at their portfolio here.